Navigation Links
Mayo Clinic Identifies Infection Risks for Patients with Inflammatory Bowel Disease
Date:4/2/2008

Patients on immunosuppressants should seek medical attention at any sign of infection

ROCHESTER, Minn., April 2, 2008 /PRNewswire-USNewswire/ -- A new Mayo Clinic study finds that patients who are 50 or older and take multiple immunosuppressive medications for inflammatory bowel disease have a higher risk for developing infections. The study is published in this month's issue of Gastroenterology.

More than 1 million Americans are believed to have ulcerative colitis or Crohn's disease, the most common forms of inflammatory bowel disease. These conditions inflame the lining of the digestive tract and cause severe bouts of watery diarrhea and abdominal pain. The cause of these conditions is not known, but the most common theory is that the immune system of patients with inflammatory bowel disease reacts abnormally to bacteria in the gut.

"Patients with inflammatory bowel disease are often treated with a combination of immunosuppressive medications to help relieve symptoms," says Edward Loftus, M.D. a Mayo Clinic gastroenterologist and an author of this study. "Since these medications compromise immune reactions in the body, patients can develop what are called opportunistic infections, or infections from common organisms that would not affect individuals with healthy immune systems."

Dr. Loftus and a team of Mayo Clinic researchers set out to identify and quantify the risk factors that are associated with opportunistic infections in inflammatory bowel disease patients. They studied the medical records of 300 patients with inflammatory bowel disease. One hundred of these patients had contracted opportunistic infections and 200 patients had no history of these infections. The team found that patients who were age 50 or older were three times more likely to have infections than younger patients. Additionally, patients on one immunosuppressive medication were three times more likely to develop opportunistic infections than those on none. Patients on two or three different immunosuppressive medications were 14 times more likely to develop opportunistic infections than those on none.

"This study shows that patients with inflammatory bowel disease who are on immunosuppressive medications should have a low threshold for seeking medical attention at any sign of infection, such as cough or fever," says Dr. Loftus. "For the medical community, this is another example of the need to be cognizant of the potential risks of combination immunosuppressive therapies."

Other members of the Mayo Clinic research team included Murat Toruner, M.D.; W. Scott Harmsen; Alan Zinsmeister, Ph.D.; Robert Orenstein, D.O.; William Sandborn, M.D.; Jean-Frederic Colombel, M.D.; and Laurence Egan, M.D.

Each year, physicians at Mayo Clinic's campuses in Arizona, Florida and Minnesota treat thousands of patients who have digestive diseases. For more information on the treatment of digestive diseases at Mayo Clinic, visit http://www.mayoclinic.org/gi.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.

CONTACT:

Elizabeth Rice

507-284-5005 (days)

507-284-2511 (evenings)

newsbureau@mayo.edu


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce that California ... members. As part of the amalgam separator endorsement, all CDA members may purchase an ... off the retail value. This partnership between PureLife and CDA is especially timely as ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance ... to communities in the greater Chicago metropolitan area, is embarking on a charity ... youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of ...
(Date:6/22/2017)... Rosa, CA (PRWEB) , ... June 22, 2017 , ... ... been named as a Top Doctor for 2017. Each year, research and information firm, ... country. First winning the title in 2015, this marks the 3rd time that ...
(Date:6/22/2017)... ... 2017 , ... The VA Maryland Health Care System has ... the Baltimore VA Medical Center, a division of the VA Maryland Health Care ... promote waste reduction and promote recycling. Also, Practice Greenhealth has recognized the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology: